In the present study, we demonstrated that the lower PgR expression levels (<20%) were significantly associated with decreased OS and PFS in patients with HR-positive/HER2-negative metastatic BC treated with first-line CDK4/6 inhibitors. This evidence concerns the gene CDK4 and breast cancer.